What Role Can Testosterone Play in Menopause Care

Why Testosterone Matters During Menopause

Testosterone is not exclusively a male hormone. Women produce testosterone in the ovaries, adrenal glands, and through peripheral conversion of androgen precursors, with circulating levels that peak in the early to mid-twenties. By the time a woman reaches natural menopause around age 51, her total testosterone has declined by approximately 50% from that peak, according to longitudinal data from the Melbourne Women's Midlife Health Project. Surgical menopause (bilateral oophorectomy) causes an even sharper drop, reducing testosterone by 40 to 50% within 48 hours of surgery [1].

This decline matters clinically. Testosterone acts on androgen receptors distributed across the brain, bone, muscle, and genital tissue. The reduction does not always produce symptoms. But when it does, the most consistently documented complaint is persistent, distressing loss of sexual desire, a condition formally classified as hypoactive sexual desire disorder (HSDD) [2]. Prevalence estimates for HSDD in postmenopausal women range from 12 to 19% in community samples, making it the most common female sexual dysfunction after menopause.

Standard estrogen-progestogen therapy addresses vasomotor symptoms and vaginal atrophy effectively. It does not reliably restore libido. That gap is where testosterone enters the clinical picture.

What the Evidence Shows for Sexual Function

The strongest evidence base for testosterone in menopause relates to sexual desire. A 2019 systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology pooled 36 randomized controlled trials enrolling 8,480 postmenopausal women. The findings were clear: testosterone therapy produced a statistically significant increase in satisfying sexual events, sexual desire, arousal, orgasm frequency, responsiveness, and self-image compared with placebo or estrogen alone [3].

The effect size was moderate but consistent. Satisfying sexual events increased by an average of 0.85 per 4-week cycle beyond placebo. That number may sound small in isolation. Placed in context, it represents a roughly 50% improvement over the baseline rate reported by participants with HSDD.

Earlier key work by Shifren and colleagues in surgically menopausal women demonstrated that transdermal testosterone at 300 mcg/day improved the Brief Index of Sexual Functioning for Women composite score by 31% over 12 weeks compared with placebo [4]. The INTIMATE NM1 trial (N=562) extended these findings to naturally menopausal women, confirming that 300 mcg/day transdermal testosterone increased satisfying sexual events by 2.1 episodes per 4-week period versus 0.98 for placebo (P<0.001) at 24 weeks [5].

One consistent observation across trials: the benefit appears limited to women who report clinically meaningful distress about their low desire. Women without distress show minimal response, which reinforces why guideline bodies restrict the recommendation to diagnosed HSDD rather than low desire alone.

Current Guidelines and Consensus Recommendations

The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed by the International Menopause Society, the Endocrine Society, the American College of Obstetricians and Gynecologists, and eight other societies, provides the most authoritative framework. The full statement, published in The Journal of Clinical Endocrinology & Metabolism, sets out specific conditions for appropriate prescribing [6]:

1. The patient is a postmenopausal woman with HSDD after other contributing factors (relationship conflict, medication side effects, depression, other medical conditions) have been investigated and addressed.
2. The formulation is transdermal (cream, gel, or patch) at a dose that approximates premenopausal physiologic levels, typically 300 to 500 mcg/day.
3. Serum total testosterone is monitored and kept below the upper limit of the premenopausal reference range.
4. A 6-month initial trial is conducted with assessment of benefit. If no meaningful improvement occurs by 6 months, therapy is discontinued.

The consensus explicitly recommends against using testosterone for general well-being, anti-aging, cognitive enhancement, or cardiovascular protection due to insufficient evidence for those indications. It also recommends against oral testosterone formulations for women because of adverse hepatic first-pass effects on lipid profiles.

The North American Menopause Society (NAMS) 2022 hormone therapy position statement echoes this position, stating that off-label transdermal testosterone may be considered for HSDD in postmenopausal women after a thorough evaluation [7].

Dosing and Formulation Specifics

No testosterone product carries FDA approval for use in women. The Intrinsa patch (300 mcg/day), approved by the European Medicines Agency in 2006, was withdrawn from the market in 2012 for commercial reasons, not safety concerns. Every testosterone prescription for a woman in the United States is therefore off-label.

The most common approach involves compounded transdermal testosterone cream at concentrations of 0.5% to 1%, applied in doses that deliver approximately 300 to 500 mcg/day [6]. Some clinicians use commercially available 1% testosterone gel marketed for men (such as AndroGel or Testim) at roughly one-tenth the male dose, typically 5 to 10 mg applied every other day or as a pea-sized amount daily. This workaround is imprecise. Compounded formulations allow more accurate low-dose delivery.

Testosterone pellets (subcutaneous implants) are used by some practitioners, particularly in Australia and certain U.S. clinics. Pellet dosing is harder to titrate and harder to reverse if supraphysiologic levels develop. The 2019 global consensus statement does not endorse pellets for women due to the risk of supraphysiologic dosing and limited pharmacokinetic data in female patients [6].

Oral DHEA (dehydroepiandrosterone) at 25 to 50 mg/day is sometimes used as an indirect route to raise testosterone, since DHEA serves as a precursor. A 2015 Cochrane-style review found DHEA had modest but inconsistent effects on sexual function in postmenopausal women, inferior to direct testosterone supplementation [8]. Intravaginal DHEA (prasterone, marketed as Intrarosa) is FDA-approved for dyspareunia due to vulvovaginal atrophy but acts primarily through local conversion to estrogen and testosterone in vaginal tissue rather than raising systemic testosterone levels.

Monitoring and Safety Profile

Short-term safety data for transdermal testosterone at physiologic doses are reassuring. The 2019 Lancet meta-analysis reported the only statistically significant adverse effects were acne and hair growth (hirsutism), both mild and generally reversible on discontinuation [3]. Acne occurred in roughly 7 to 8% of testosterone-treated women versus 3 to 4% on placebo. Voice deepening, clitoromegaly, and androgenic alopecia were not observed at physiologic doses across the pooled trials.

Cardiovascular safety data from randomized trials extend to approximately 24 months. No increase in cardiovascular events was detected. A post-hoc analysis of pooled RCT data involving over 3,000 women found no difference in blood pressure, lipid profiles, or glucose metabolism between testosterone and placebo groups at physiologic doses [6].

Breast cancer risk is a frequent concern. The pooled trial data show no increased incidence of breast cancer with testosterone use up to 24 months. Observational data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort suggested an association between higher endogenous testosterone levels and breast cancer risk, but this does not directly translate to exogenous therapy at physiologic replacement doses [9]. The 2019 consensus statement concluded that "data are insufficient to draw conclusions regarding breast cancer risk" and recommended ongoing surveillance during treatment.

Monitoring during therapy should include:

• Baseline and 6-week serum total testosterone (and free testosterone if available)
• Lipid panel at baseline and annually
• Liver function tests at baseline
• Assessment of androgenic side effects at each visit
• Validated sexual function questionnaire (such as the FSFI or FSDS-R) at baseline, 3 months, and 6 months to assess therapeutic response

Benefits Beyond Sexual Function

Research into non-sexual benefits of testosterone for menopausal women remains early-stage but active. Several areas show preliminary signals.

Bone mineral density. A 2-year randomized trial of transdermal testosterone (300 mcg/day) in 261 postmenopausal women found a significant increase in lumbar spine and hip bone mineral density compared with placebo, independent of estrogen use [5]. The magnitude of the increase (approximately 2% at the spine) was clinically meaningful, though fracture reduction data are not available.

Body composition. Testosterone therapy in postmenopausal women has been associated with small increases in lean body mass and reductions in fat mass. A 2006 trial of 51 postmenopausal women receiving sublingual testosterone (40 mcg twice daily) with estrogen showed increased lean mass by 1.2 kg and decreased fat mass by 1.3 kg over 24 weeks compared with estrogen alone [10].

Mood and well-being. The data here are mixed. Some RCTs reported improvements in depressed mood and fatigue with testosterone therapy, but the 2019 meta-analysis found that the pooled effect on psychological well-being did not reach statistical significance across all trials [3]. Individual women may experience mood benefits, but this is not a reliable or recommended indication.

Cognitive function. Animal studies and small human trials have suggested testosterone may support verbal memory and processing speed. The WISDOM study and a small Australian RCT of 92 postmenopausal women found no significant cognitive benefit from 26 weeks of transdermal testosterone [11]. Larger, longer trials are needed before any conclusions can be drawn.

The 2019 global consensus statement is explicit: the only evidence-based indication for testosterone therapy in postmenopausal women is HSDD. All other potential benefits remain investigational.

Who Should Not Receive Testosterone

Contraindications and cautions overlap with those for any androgen therapy. Testosterone should not be prescribed to women with androgen-sensitive cancers (including hormone receptor-positive breast cancer), polycystic ovary syndrome with existing hyperandrogenism, or severe acne or hirsutism [6]. Pregnancy is an absolute contraindication due to the risk of virilization of a female fetus.

Women with active cardiovascular disease, uncontrolled hypertension, or significant hepatic dysfunction require individualized risk-benefit assessment. Oral testosterone is contraindicated in all women due to hepatic first-pass effects that worsen lipid profiles and may increase thrombotic risk.

Premenopausal women represent a separate clinical population. The 2019 consensus statement explicitly notes that evidence is insufficient to support testosterone use for sexual dysfunction in premenopausal women, and that different physiologic considerations apply.

The Regulatory Gap and Compounding Concerns

The absence of an FDA-approved testosterone product for women creates a structural problem. Clinicians must either dose-adjust male products or rely on compounding pharmacies. Both approaches introduce variability.

Compounded testosterone creams and gels are not subject to the same quality standards as commercially manufactured pharmaceuticals. A 2019 study published in JAMA Internal Medicine tested 12 compounded hormone therapy products and found that 34% fell outside acceptable potency ranges [12]. This means some women receive subtherapeutic doses while others receive supraphysiologic doses, neither of which is desirable.

The Endocrine Society and the International Menopause Society have repeatedly called for development and FDA approval of a female-specific testosterone formulation. Dr. Susan Davis, a lead author of the 2019 global consensus statement and professor of women's health at Monash University, has noted that the regulatory gap "leaves women and their clinicians in an untenable position" where the evidence supports a treatment that cannot be reliably delivered through existing products.

Until a standardized product reaches the market, clinicians should use accredited compounding pharmacies (PCAB-accredited or state-inspected) and verify testosterone levels 3 to 6 weeks after initiation to confirm appropriate dosing.

Practical Decision Framework for Clinicians and Patients

A structured approach reduces both under-treatment and overuse:

1. Screen for HSDD using a validated instrument such as the Decreased Sexual Desire Screener (DSDS). Low desire alone is not sufficient for diagnosis; personal distress about the low desire is required.
2. Exclude reversible causes. Review medications (SSRIs, antiandrogens, aromatase inhibitors). Assess relationship factors. Screen for depression and anxiety. Evaluate thyroid function.
3. Optimize existing HRT first. Adequate estrogen replacement resolves vaginal dryness and dyspareunia in many cases. Confirm the current regimen is appropriate before adding testosterone.
4. Initiate transdermal testosterone at 300 mcg/day. Check serum total testosterone at 3 to 6 weeks.
5. Assess response at 3 and 6 months using the same validated instrument. If no meaningful benefit by 6 months, discontinue.
6. Monitor annually with testosterone levels, lipid panel, and clinical assessment for androgenic side effects.

Testosterone therapy for menopause-related HSDD, when prescribed within guideline parameters, carries a favorable risk-benefit profile over 24 months of observation. The recommended starting dose for transdermal testosterone in postmenopausal women is 300 mcg/day, with serum levels maintained below 70 ng/dL.